Key Takeaways Novo Nordisk reported that Wegovy cut cardiovascular risk more than Eli Lilly's tirzepatide.Wegovy patients saw 57% fewer major events when staying on treatment without long gaps.Including all users, Wegovy showed a 29% lower risk of heart attack, stroke, or death.Novo Nordisk (NVO) announced data from a head-to-head study evaluating the risk of major adverse cardiovascular events with Wegovy compared with Eli Lilly’s (LLY) tirzepatide in patients with overweight or obesity and established car ...